Takeda Ventures was among the participants in a $46.5m round closed nearly a year after its parent company launched a partnership with the Institut Curie spinout.
Egle Therapeutics, a France-based T-cell therapy developer spun out of Institut Curie, closed a €40m ($46.5m) series A round late last month that included Takeda Ventures, the strategic investment arm of pharmaceutical firm Takeda.
Public investment bank Bpifrance’s InnoBio 2 fund co-led the round with life sciences investment firm LSP, and it also featured venture capital fund Fund+ and investment firm Bioqube Ventures.
Egle is working on immunotherapies designed to fight cancer and autoimmune diseases by targeting immune suppressor regulatory…